Table 1.
Baseline characteristics
| Lanreotide [n = 124] |
Standard of care [n = 125] | p value | |
|---|---|---|---|
| Female | 58 (47) | 62 (50) | 0.66 |
| Age, years | 48 ± 7 | 49 ± 7 | 0.54 |
| BMI, kg/m2 | 27.0 ± 4.2 | 27.2 ± 4.8 | 0.74 |
| Height-adjusted total liver volume, mL [median (IQR)] | 1165 (9868–1574) | 1141 (962–1333) | 0.06 |
| Polycystic liver disease classification | |||
| Mild [hTLV <1600 mL/m] | 95 (76.6) | 112 (89.6) | |
| Moderate [hTLV 1600–3200 mL] | 24 (19.4) | 11 (8.8) | |
| Severe [hTLV >3200 mL] | 5 (4.0) | 2 (1.6) | 0.02 |
| eGFR CKD-EPI, mL/1.73m2/min | 50.4 ± 11.3 | 50.1 ± 11.1 | 0.82 |
| AST, U/L [median (IQR)] | 23.0 (19.5–27.5) | 23.0 (20.0–28.0) | 0.58 |
| ALT, U/L [median (IQR)] | 23.0 (18.0–29.0) | 21.0 (16.0–27.0) | 0.15 |
| ALP, U/L [median (IQR)] | 67.0 (56.0–80.0) | 66.0 (55.3–77.8) | 0.58 |
| GGT, µmol/L [median (IQR)] | 33.0 (23.5–49.0) | 29.0 (1.25–47.0) | 0.08 |
| Bilirubin direct, µmol/L [median (IQR)] | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) | 0.008 |
| Bilirubin indirect, µmol/L [median (IQR)] | 6.0 (4.0–8.0) | 6.0 (4.0–7.0) | 0.57 |
Data are expressed as means ± standard deviation or median (interquartile range) in the case of non-normal data distribution, or number (percentage) in the case of categorical data
Significant p-values are highlighted in bold
BMI body mass index, eGFR estimated glomerular filtration rate, hTLV height-adjusted liver volume, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT γ-glutamyltransferase, IQR interquartile range, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration